Posts

Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain.

/by

Authors: Epifanio Mondello, Domenico Quattrone, Luigi Cardia, Giuseppe Bova, et al
Journal of Pain Research, 6 September 2018
—
OBJECTIVE: This study aimed to evaluate pain and its symptoms in patients with failed back surgery syndrome (FBSS) refractory to other therapies, treated with a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in association with spinal cord stimulation…

Read more

Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

/by

Authors: Gregory T. Carter, Aaron M. Flanagan, Mitchell Earleywine, Donald I. Abrams, et al
American Journal of Hospice and Palliative Medicine, August 2011
—
Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I…

Read more

Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.

/by

Authors: Vincent Maida, Marguerite Ennis, Shiraz Irani, Mario Corbo, Michael Dolzhykov
Journal of Supportive Oncology, March 2008
—
A prospective observational study assessed the effectiveness of adjuvant nabilone (Cesamet) therapy in managing pain and symptoms experienced by advanced cancer patients. The primary outcomes were the differences between treated and untreated patients at 30 days’ follow-up, in…

Read more